ACEON® is contraindicated in patients known to be hypersensitive to this product or to any other ACE inhibitor, and in patients with a history of angioedema related to previous treatment with an ACE inhibitor. 2
Another ACE inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially patients with a collagen vascular disease such as systemic lupus erythematosus or scleroderma. Available data are insufficient to show whether ACEON® causes agranulocytosis at similar rates. 2
In patients with stable coronary artery disease, ACEON® Tablets should be given at an initial dose of 4 mg once daily for 2 weeks, and then increased as tolerated, to a maintenance dose of 8 mg once daily
In elderly CAD patients (>70 years), ACEON® should be given as a 2 mg dose once daily in the first week, followed by 4 mg once daily in the second week, and 8 mg once daily for maintenance dose if tolerated
In patients with essential hypertension, the recommended dose of ACEON® is 4 mg once daily. The dose may be titrated upward to a maximum 16 mg/day (8 mg/day in elderly patients >65 years) until BP is controlled.The usual maintenance dose is 4 mg to 8 mg once daily
In hypertensive patients with minimal renal impairment (CrCl >30 mL/min), the initial dosage should be 2 mg/day, and dosage should not exceed 8 mg/day due to limited clinical experience
In patients currently being treated with a diuretic, symptomatic hypotension occasionally can occur following the initial dose of perindopril. To reduce likelihood of such reaction, the diuretic should, if possible, be discontinued 2 to 3 days prior to the beginning of ACEON® Tablets therapy. Then, if blood pressure is not controlled with ACEON® Tablets alone, the diuretic should be resumed. After the first dose of ACEON® Tablets, the patient should be followed closely for the first two weeks of treatment and whenever the dose of ACEON® Tablets and/or diuretics is increased
When qd and bid dosing were compared, the bid regimen was generally slightly superior, but not by more than about 0.5 to 1 mm Hg
